



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Potassium clavulanate/amoxicillin hydrate

October 17, 2017

Non-proprietary name

Potassium clavulanate/amoxicillin hydrate

Safety measure

Precautions should be revised in the package insert.

In the Clinically Significant Adverse Reactions subsection of the Adverse Reactions section, the following text should be revised (underlined parts are revised):

Agranulocytosis, granulocytopenia, thrombocytopenia:

Agranulocytosis, granulocytopenia, thrombocytopenia may occur. Patients should be carefully monitored by means such as performing blood tests. If any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be taken.